Literature DB >> 26322521

Inhibition and Allosteric Regulation of Monomeric Phosphoenolpyruvate Carboxykinase by 3-Mercaptopicolinic Acid.

Marc D Balan1, Matthew J Mcleod2, William R Lotosky2, Mark Ghaly2, Todd Holyoak2,1.   

Abstract

For almost 40 years, it has been known that tryptophan metabolites and picolinic acid analogues act as inhibitors of gluconeogenesis. Early studies observed that 3-mercaptopicolinic acid (MPA) was a potent hypoglycemic agent via inhibition of glucose synthesis through the specific inhibition of phosphoenolpyruvate carboxykinase (PEPCK) in the gluconeogenesis pathway. Despite prior kinetic investigation, the mechanism of the inhibition by MPA is unclear. To clarify the mechanism of inhibition exerted by MPA on PEPCK, we have undertaken structural and kinetic studies. The kinetic data in concert with crystallographic structures of PEPCK in complex with MPA and the substrates for the reaction illustrate that PEPCK is inhibited by the binding of MPA at two discrete binding sites: one acting in a competitive fashion with PEP/OAA (∼10 μM) and the other acting at a previously unidentified allosteric site (Ki ∼ 150 μM). The structural studies suggest that binding of MPA to the allosteric pocket stabilizes an altered conformation of the nucleotide-binding site that in turn reduces the affinity of the enzyme for the nucleotide.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26322521     DOI: 10.1021/acs.biochem.5b00822

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

Review 1.  Dysregulation of metabolic enzymes in tumor and stromal cells: Role in oncogenesis and therapeutic opportunities.

Authors:  Mohammad Aslam Khan; Haseeb Zubair; Shashi Anand; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Cancer Lett       Date:  2020-01-07       Impact factor: 8.679

2.  Inhibition of Pig Phosphoenolpyruvate Carboxykinase Isoenzymes by 3-Mercaptopicolinic Acid and Novel Inhibitors.

Authors:  Jorge Hidalgo; Pedro Latorre; José Alberto Carrodeguas; Adrián Velázquez-Campoy; Javier Sancho; Pascual López-Buesa
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

3.  The phosphoenolpyruvate carboxykinase (PEPCK) inhibitor, 3-mercaptopicolinic acid (3-MPA), induces myogenic differentiation in C2C12 cells.

Authors:  Madelaine C Brearley; Zoe C T R Daniel; Paul T Loughna; Tim Parr; John M Brameld
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

4.  Enhancing glucose metabolism via gluconeogenesis is therapeutic in a zebrafish model of Dravet syndrome.

Authors:  Rajeswari Banerji; Christopher Huynh; Francisco Figueroa; Matthew T Dinday; Scott C Baraban; Manisha Patel
Journal:  Brain Commun       Date:  2021-01-25

5.  NFYA promotes the anti-tumor effects of gluconeogenesis in hepatocellular carcinoma through the regulation of PCK1 expression.

Authors:  Goki Tsujimoto; Rin Ito; Kei Yoshikawa; Chihiro Ueki; Nobuhiro Okada
Journal:  Front Cell Dev Biol       Date:  2022-08-25

6.  PGC-1β and ERRα Promote Glutamine Metabolism and Colorectal Cancer Survival via Transcriptional Upregulation of PCK2.

Authors:  Danielle E Frodyma; Thomas C Troia; Chaitra Rao; Robert A Svoboda; Jordan A Berg; Dhananjay D Shinde; Vinai C Thomas; Robert E Lewis; Kurt W Fisher
Journal:  Cancers (Basel)       Date:  2022-10-05       Impact factor: 6.575

7.  c.A2456C-substitution in Pck1 changes the enzyme kinetic and functional properties modifying fat distribution in pigs.

Authors:  Pedro Latorre; Carmen Burgos; Jorge Hidalgo; Luis Varona; José Alberto Carrodeguas; Pascual López-Buesa
Journal:  Sci Rep       Date:  2016-01-21       Impact factor: 4.379

8.  Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma.

Authors:  Meng-Xi Liu; Lei Jin; Si-Jia Sun; Peng Liu; Xu Feng; Zhou-Li Cheng; Wei-Ren Liu; Kun-Liang Guan; Ying-Hong Shi; Hai-Xin Yuan; Yue Xiong
Journal:  Oncogene       Date:  2018-01-16       Impact factor: 9.867

9.  Computational evaluation of natural compounds as potential inhibitors of human PEPCK-M: an alternative for lung cancer therapy.

Authors:  Luiz Phillippe R Baptista; Vanessa Vc Sinatti; Joao Hm Da Silva; Laurent Emmanuel Dardenne; Ana Carolina Guimarães
Journal:  Adv Appl Bioinform Chem       Date:  2019-08-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.